在非小细胞肺癌中,CD8+ T-细胞特征作为预后和免疫疗法反应预测器
Tienan Zhao1, Sarinder Kaur Dhillon2
1Data Science and Bioinformatics Laboratory, Institute of Biological Sciences, Faculty of Science, University of Malaya, Kuala Lumpur, Malaysia.
Folia biologica
|December 18, 2024
概括
研究人员确定了一种基于CD8+T细胞标记物的新生物标志物签名,用于预测非小细胞肺癌 (NSCLC) 的治疗反应. 这一发现为改善NSCLC患者免疫疗法的疗效提供了希望.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 基因组学就是基因组学.
背景情况:
- 非小细胞肺癌 (NSCLC) 占肺癌的85%,存活率低.
- 目前的免疫疗法只对一小部分NSCLC患者有益,因此需要预测性生物标志物.
- CD8+ T 细胞对于抗癌免疫和免疫治疗反应至关重要.
研究的目的:
- 确定和验证一种新的生物标志物签名,用于预测NSCLC的预后和免疫治疗反应.
- 研究CD8+ T细胞在NSCLC患者结局中的作用.
- 为个性化NSCLC治疗策略开发一个强大的生物标志物.
主要方法:
- 在四个NSCLC样本上利用单细胞RNA测序 (scRNA-seq).
- 从癌症基因组图谱 (TCGA) 中分析了1000个NSCLC样本.
- 包括来自GSE37745队列的196个NSCLC样本进行验证.
主要成果:
- 基于CD8+T细胞标记基因的新生物标记特征被确定.
- 在NSCLC患者中有利的风险概况与特定的免疫细胞模式相关联.
- 证实CD8+ T细胞是NSCLC预后和治疗疗效的关键预测因子.
结论:
- 开发的生物标志物签名有效预测NSCLC的治疗反应.
- CD8+ T 细胞在NSCLC的进展和对免疫治疗的反应中发挥着关键作用.
- 这种签名可以指导NSCLC患者的个性化治疗决策,改善结果.
相关概念视频
01:27Tumor Immunotherapy
475
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
475
02:39lncRNA - Long Non-coding RNAs
8.5K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.5K